Collegium Pharmaceutical, Inc.

NASDAQ:COLL

Drug Manufacturers - Specialty & Generic

Healthcare
$25.93 -0.71%

-$0.24 today

Market cap
$805.79M
Beta
0.75
P/E (TTM)
14.3
EPS (TTM)
$2.34
52W Low $29.19High $50.79

Volume 0.49M

Average 0.50M

COLL EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Collegium Pharmaceutical, Inc.NASDAQ: COLL

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA grows, but more slowly than its trailing trend

Q1 FY2026 EBITDA of $90.54M rose 12.5% year over year, behind the +83.3% change in trailing-twelve-month EBITDA. Sequentially, it fell 70.2% from the prior quarter. Over 3 fiscal years it compounded at +32.3% a year.

Context

  • EBITDA amounted to 51.4% of revenue in FY2025, down 2.7 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 5 analysts of $637.42M (+59.0%) for the fiscal year ending Dec 2026, a step up from the +17.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$90.54M-70.2% QoQ
Last fiscal yearDec 2025
$401.01M+17.4% YoY
LTMMar 2026
$609.91M+83.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.5%+80.7%+68.2 pp
1 year+17.4%+59.0%+41.6 pp
3-year CAGR+32.3%+8.8%-23.5 pp
5-year CAGR+12.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
401.01M USD
Year-over-year change
+17.4%
4-year CAGR
+46.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How COLL compares with its peers on the latest reported figures

  • COLL's LTM Mar 2026 EBITDA of $609.91M is the highest of the 3 companies compared; the peer median is -$127.97M.
  • Its year-over-year change of +83.3% is the 2nd highest of 3, against a peer median of -69.9%.
  • EBITDA amounts to 76.6% of revenue for COLL, versus a peer median of 560.8%.
COLL Competitors Peer median
EBITDA for COLL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$609.91M +83.3%+32.3%76.6%
PCRXPacira BioSciences, Inc.LTM Mar 2026$118.4M +322.5%-4.4%16.1%
SCLXScilex Holding CompanyLTM Mar 2026-$374.35M -462.2%—1105.5%
LTGOLatigo Biotherapeutics Inc.—— ———
Peer median (excluding COLL) -$127.97M-69.9%-4.4%560.8%

Competitors are the stored peer set for COLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue276.87M463.93M566.77M631.45M780.57M
Cost of Revenue126.25M254.45M240.6M254.11M317.31M
Gross Profit150.62M209.49M326.17M377.34M463.26M
Gross Margin54.4%45.2%57.5%59.8%59.3%
Research & Development9.45M3.98M000
Selling, General & Admin118.96M172.19M159.21M182.98M276.17M
Operating Expenses132.99M176.17M159.21M207.45M276.17M
Depreciation & Amortization68.92M138.94M149.26M169.16M226.07M
EBITDA86.56M173.31M308.33M341.7M401.01M
EBITDA Margin31.3%37.4%54.4%54.1%51.4%
Operating Income17.63M33.32M166.96M169.9M187.08M
Operating Margin6.4%7.2%29.5%26.9%24.0%
Interest Income12K1.05M15.62M13.98M11.29M
Interest Expense21.01M63.21M83.34M73.97M82.31M
Other Income / Expenses(21M)(62.17M)(91.23M)(71.33M)(94.47M)
Income Before Tax(3.37M)(28.85M)75.73M98.57M92.62M
Pre-Tax Margin-1.2%-6.2%13.4%15.6%11.9%
Income Tax Expense(74.89M)(3.85M)27.58M29.38M29.75M
Net Income71.52M(25M)48.16M69.19M62.87M
Net Margin25.8%-5.4%8.5%11.0%8.1%
EPS (Basic)2.05(0.74)1.602.141.98
EPS (Diluted)1.86(0.74)1.291.861.73
Weighted Avg Shares34.94M33.83M33.74M32.27M31.71M
Weighted Avg Shares (Diluted)41.05M33.83M41.79M40.42M39.7M

Collegium Pharmaceutical, Inc.

NASDAQ:COLL

Intrinsic Alpha fair value

Locked

Current Price

$25.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.